title: The use of abciximab associated with primary angioplasty for treating acute myocardial infarction.
abstract: OBJECTIVE
  To assess the benefit resulting from the use of abciximab associated with primary angioplasty. The following parameters were analyzed in-hospital, at 30 days, and 6 months: (a) flow in the culprit artery; (b) ventricular function; (c) combined outcome of death, acute myocardial infarction, and additional revascularization.
  
  
  METHODS
  From November 1997 to June 1999, a longitudinal nonrandomized study with historical data of 137 patients with acute myocardial infarction within the first 12 hours. Patients undergoing primary angioplasty and were divided into 2 groups: those receiving (A) abciximab (26) or (B) conventional therapy (111). TIMI flow and regional ventricular function estimated by the standard deviation (SD)/chordis index were analyzed.
  
  
  RESULTS
  At the end of angioplasty, TIMI 3 flow was observed in 76.9% and 83.8% of the patients in groups A and B, respectively (P=0.58). In the reevaluation, patients with TIMI flow <3 showed a 100% improvement in group A and a 33% in group B (P<0.0001). A significant improvement (P<0.0001) in regional ventricular function, by SD/chordis index, occurred in each group; no significant difference between groups however, was observed (29.9% x 20.2%; P=0.58). A nonsignificant reduction in the combined outcome in the in-hospital phase (3.85% A x 9.0% B; P=0.34) and on the 30th day (4.0% x 12.0%; P=0.22) was observed in group A.
  
  
  CONCLUSIONS
  Abciximab improved blood flow. Primary angioplasty improved regional ventricular function independent of antithrombotic therapy. Abciximab showed a trend toward reducing the combined outcome in the in-hospital phase and on the 30th day.
authors.forename: Manuel Lisandro Hernández
authors.initials: ML
authors.lastname: Brito
authors.forename: Newton F Stadler de
authors.initials: NF
authors.lastname: Souza Filho
authors.forename: Alvaro Vieira
authors.initials: AV
authors.lastname: Moura  V
authors.forename: Luiz Augusto
authors.initials: LA
authors.lastname: Lavalle
authors.forename: Rubens Zenobio
authors.initials: RZ
authors.lastname: Darwich
authors.forename: Marisa
authors.initials: M
authors.lastname: Leal
authors.forename: Eva Cantalejo
authors.initials: EC
authors.lastname: Munhoz
mesh_terms: D000077284:Abciximab; D017130:Angioplasty / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D016276:Ventricular Function
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab